Reconfiguring COVID and influenza vaccines for long-term effectiveness
pharmaphorum
SEPTEMBER 22, 2022
Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology.
Let's personalize your content